MedTrace Logo

Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

NCT06458803 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2024-06-17

No results posted yet for this study

Summary

Immune thrombocytopenia (ITP) is a haemorrhagic disorder often associated with CTD. Corticosteroids are the first-line treatment for CTD-associated thrombocytopenia, but not all patients respond well. Eltrombopag is an oral, small molecule thrombopoietin receptor agonist. It interacts with the transmembrane domain of the thrombopoietin receptor and stimulates platelet production. This study is designed to evaluate the efficacy and safety of eltrombopag in patients with refractory CTD-ITP. It is a single-centre, retrospective, observational study involving a cohort of 52 patients diagnosed with CTD-RITP who received eltrombopag between 2013 and 2023. Follow-up data will be systematically collected and analysed to evaluate the therapeutic efficacy and safety of the drug. The study will provide valuable insight into the benefit of eltrombopag in CTD-RITP by reviewing baseline characteristics and performing subsequent clinical assessments to determine drug response and adverse events.

Conditions

  • Refractory Thrombocytopenia
  • Connective Tissue Diseases

Interventions

DRUG

Eltrombopag

patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Lingli Dong, MD · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-06
Primary Completion
2023-05-11
Completion
2023-11-19

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06458803 on ClinicalTrials.gov